In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Commentary|Videos|January 8, 2025
Hodgkin Lymphoma: Overview and Update
Author(s)Ann S. LaCasce, MD, MMSc
Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.
Advertisement
Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.
Advertisement
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5